Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:4044346rdf:typepubmed:Citationlld:pubmed
pubmed-article:4044346lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:4044346lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:4044346lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:4044346lifeskim:mentionsumls-concept:C0851346lld:lifeskim
pubmed-article:4044346lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:4044346lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:4044346lifeskim:mentionsumls-concept:C1264633lld:lifeskim
pubmed-article:4044346lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:4044346lifeskim:mentionsumls-concept:C0086960lld:lifeskim
pubmed-article:4044346lifeskim:mentionsumls-concept:C1554217lld:lifeskim
pubmed-article:4044346pubmed:issue10lld:pubmed
pubmed-article:4044346pubmed:dateCreated1985-10-29lld:pubmed
pubmed-article:4044346pubmed:abstractTextThirty-five tumors in 14 patients with metastatic or recurrent malignant melanoma were randomized to high dose per fraction radiotherapy at either 9 Gy X 3 or 5 Gy X 8 twice weekly. Complete and persistent regression was found in 24/35 (69%) and partial response in 10/35 of the tumors. The overall response rate was 97%. No difference was observed between the two treatment regimens. Acute and late radiation damage to normal tissue was acceptable and of the same magnitude in both schedules.lld:pubmed
pubmed-article:4044346pubmed:languageenglld:pubmed
pubmed-article:4044346pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4044346pubmed:citationSubsetIMlld:pubmed
pubmed-article:4044346pubmed:statusMEDLINElld:pubmed
pubmed-article:4044346pubmed:monthOctlld:pubmed
pubmed-article:4044346pubmed:issn0360-3016lld:pubmed
pubmed-article:4044346pubmed:authorpubmed-author:OvergaardJJlld:pubmed
pubmed-article:4044346pubmed:authorpubmed-author:OvergaardMMlld:pubmed
pubmed-article:4044346pubmed:authorpubmed-author:von der...lld:pubmed
pubmed-article:4044346pubmed:issnTypePrintlld:pubmed
pubmed-article:4044346pubmed:volume11lld:pubmed
pubmed-article:4044346pubmed:ownerNLMlld:pubmed
pubmed-article:4044346pubmed:authorsCompleteYlld:pubmed
pubmed-article:4044346pubmed:pagination1837-9lld:pubmed
pubmed-article:4044346pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:4044346pubmed:meshHeadingpubmed-meshheading:4044346-...lld:pubmed
pubmed-article:4044346pubmed:meshHeadingpubmed-meshheading:4044346-...lld:pubmed
pubmed-article:4044346pubmed:meshHeadingpubmed-meshheading:4044346-...lld:pubmed
pubmed-article:4044346pubmed:meshHeadingpubmed-meshheading:4044346-...lld:pubmed
pubmed-article:4044346pubmed:meshHeadingpubmed-meshheading:4044346-...lld:pubmed
pubmed-article:4044346pubmed:meshHeadingpubmed-meshheading:4044346-...lld:pubmed
pubmed-article:4044346pubmed:meshHeadingpubmed-meshheading:4044346-...lld:pubmed
pubmed-article:4044346pubmed:meshHeadingpubmed-meshheading:4044346-...lld:pubmed
pubmed-article:4044346pubmed:year1985lld:pubmed
pubmed-article:4044346pubmed:articleTitleA randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma.lld:pubmed
pubmed-article:4044346pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:4044346pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:4044346pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:4044346pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:4044346pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:4044346lld:pubmed